Phaseline

Targets › SERPINC1

SERPINC1 (Antithrombin-III): drug programs, companies and trials

20 programs from 15 companies in 24 trials: 12 Phase 4, 6 Phase 3, 5 Phase 2, 1 Phase 1; Oncology, Cardiovascular, Other; next expected readout Dec 2026.

Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. (UniProt, P01008)

Open in Phaseline: the race on SERPINC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tzu-Fei WangDalteparin Sodium
Antithrombin-III activator
SERPINC1Phase 4Cancer-associated ThrombosisDec 2026
Tzu-Fei WangEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 4Cancer-associated ThrombosisDec 2026
Tzu-Fei WangTinzaparin Sodium
Antithrombin-III activator
SERPINC1Phase 4Cancer-associated ThrombosisDec 2026
University of California, IrvineEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 4Pregnancy, High RiskDec 2026
PAEC General Hospital, IslamabadEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 4OligohydramniosJan 2027
Medical University of ViennaEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 4Respiratory InsufficiencyJan 2027
Helsinki University Central HospitalDalteparin Sodium
Antithrombin-III activator
SERPINC1Phase 4Pancreas Cancer; Liver CancerFeb 2027
Helsinki University Central HospitalEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 4Pancreas Cancer; Liver CancerFeb 2027
Helsinki University Central HospitalTinzaparin Sodium
Antithrombin-III activator
SERPINC1Phase 4Pancreas Cancer; Liver CancerFeb 2027
OctapharmaHuman plasma derived antithrombin (Atenativ)
Antithrombin (plasma-derived)
SERPINC1Phase 3Congenital Antithrombin Deficiency; Acquired Antithrombin DeficiencyDec 2026
Sunnybrook Health Sciences CentreDalteparin Sodium
Antithrombin-III activator
SERPINC1Phase 3Traumatic Brain InjuryDec 2026
Queen Mary University of LondonEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 3ThrombosisAug 2028
Queen Mary University of LondonTinzaparin Sodium
Antithrombin-III activator
SERPINC1Phase 3ThrombosisAug 2028
SanofiFitusiran
Antithrombin mRNA RNAi inhibitor
SERPINC1Phase 3Hemophilia–
Endeavor HealthEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 2Adverse Pregnancy OutcomeMar 2027
Yale UniversityEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 2Deep Venous ThrombosisApr 2027
University Hospital, LinkoepingTinzaparin Sodium
Antithrombin-III activator
SERPINC1Phase 2Epithelial Ovarian CancerDec 2027
Instituto GrifolsAT-III concentrate (ATIII-DAF/DI)
Antithrombin III (plasma-derived concentrate)
SERPINC1Phase 2Antithrombin III Deficiency–
European Foundation for Study of Chronic Liver FailureEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 2Liver Cirrhosis–
Cairo UniversityEnoxaparin Sodium
Antithrombin-III activator
SERPINC1Phase 1Deep Venous Thrombosis–

Conditions

Pancreas Cancer (3) Liver Cancer (3) Cancer-associated Thrombosis (3) Thrombosis (2) Deep Venous Thrombosis (2) Adverse Pregnancy Outcome (1) Pregnancy, High Risk (1) Liver Cirrhosis (1) Epithelial Ovarian Cancer (1) Respiratory Insufficiency (1) Traumatic Brain Injury (1) Congenital Antithrombin Deficiency (1)

Modalities

small molecule (15), protein or peptide (3), mixed (1), other (1)

Companies

Helsinki University Central Hospital (3) Tzu-Fei Wang (3) Queen Mary University of London (2) Endeavor Health (1) University of California, Irvine (1) Yale University (1) European Foundation for Study of Chronic Liver Failure (1) Cairo University (1) University Hospital, Linkoeping (1) Medical University of Vienna (1) Sunnybrook Health Sciences Centre (1) Octapharma (1) PAEC General Hospital, Islamabad (1) Instituto Grifols (1) Sanofi (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.